Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series

Nivolumab is an anti‐PD‐1 blocking monoclonal antibody approved for the treatment of non‐small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed the clinical...

全面介紹

Na minha lista:
書目詳細資料
發表在:Thorac Cancer
Main Authors: Kanazu, Masaki, Edahiro, Ryuya, Krebe, Hiroyuki, Nishida, Kohei, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
格式: Artigo
語言:Inglês
出版: John Wiley & Sons Australia, Ltd 2018
主題:
Case Reports
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275832/
https://ncbi.nlm.nih.gov/pubmed/30328672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12894
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍